Peer-reviewed veterinary case report
Safety and dosing of TriN 2755 chemo drug in dogs with tumors
By Athanasiadi, I et al.·Published in Veterinary and comparative oncology·2017·Vetsuisse Faculty·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study.
- Species:
- dog
Plain-English summary
Thirty dogs with tumors were given a new chemotherapy drug called TriN 2755 to see how well it worked and how much their bodies could handle. The treatment involved giving the drug through an IV over 20 minutes for three cycles, with doses starting at 25 mg per kg and going up to a maximum of about 74.6 mg per kg. While some dogs experienced gastrointestinal issues, nearly half of the dogs showed a positive response to the treatment, with some experiencing partial remission. The dogs that responded had a median time without disease progression of about 47 days.
People also search for: dog cancer treatment options · TriN 2755 for dogs · chemotherapy side effects in dogs
Abstract
TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kgand the MTD was 74.6 mg kg. Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25689225/